In the recently released CY2019 Medicare Outpatient Prospective Payment System (OPPS) final rule, CMS finalized further cuts to the 340B Drug Pricing Program by slashing payment to nonexcepted off-campus provider-based departments (PBDs) and biosimilar products without pass-through status. For background, PBDs form when hospitals acquire physician offices. A non-excepted PBD is one that does not […]
In the flurry of calls for increased transparency and clarification regarding the 340B Drug Discount Program, the American Hospital Association (AHA) and individual 340B hospitals have issued a set of stewardship principles. In a press release, Rick Pollack, President and CEO of the AHA, said these “340B stewardship principles will help hospitals better tell their […]
Several hospital groups recently sued the U.S. Department of Health and Human Services (HHS). This latest complaint asks the federal court to require HHS to issue rulemaking for 340B ceiling prices and accompanying penalties for manufacturers that fail to comply within 30 days of ruling. The plaintiffs in the lawsuit “collectively represent virtually every 340B […]
Several hospital groups recently refiled a lawsuit against the Trump Administration for cuts to the 340B Drug Discount Program under the Hospital Outpatient Prospective Payment System (OPPS) Final Rule for CY 2018. The litigation, led by the American Hospital Association, America’s Essential Hospitals and the Association of American Medical Colleges, alleges that 340B payment reductions […]
Read our latest specialty pharmacy insight report here.